Clinical Trial Update: A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the safety and tolerability of odronextamab in combination with cemiplimab in adults with relapsed/refractory aggress…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Lymphoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Odronextamab (odronextamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING